ACE2 and COVID-19: Finally, if ACE2 and Ang II clearly play a role in the thrombosis and cardiovascular complications following the COVID-19 mRNA vaccine, it has also been suggested that another physiopathological mechanism can sometimes trigger the cerebral venous sinus thrombosis (CVST) and cerebral venous thrombosis observed after vaccination with an adenoviral-vector-based vaccine [105].